Vonoprazan – A novel edition in the treatment of acid – Related disorders

Vonoprazan is the new drug indicated in the short term management of H. Pylori Infection, Peptic Ulcer disease and Gastroesophageal reflux Disease. The drug is used in the combination with Amoxicillin and Erythromycin .

Note the Mechanism of action:

• Vonoprazan is the potassium – Competitive acid inhibitor. It inhibits the acid formation at the secretory surface of the Gastric parietal cell By blocking the H+,K+ ATPase enzyme system via competitive inhibition.

Contraindications :

• Concomitant use with Colchicine in patient with hepatic and Renal impairment

• Concomitant use with Lipid lowering agents suchas Lovastatin, Simvastatin, Lomitapide

• Patients with eGFR < 30ml/min

•History of Intolerance to clarithromycin

• Moderate to severe hepatic impairment

Adverse Effects :

• As per the Studies, Drug seems Tobe Safe and Well Tolerated. However, Long term acid Suppression Can lead to common adverse effects such as anemia, Malabsorption, hypochlorhydria, and elevation of serum Gastrin levels.

Reference : https://www.uptodate.com/contents/antiulcer-medications -mechanism-of-action -Pharmacology -and side-effects ?search=Vonoprazan&sectionRank=1&usage_type=default&anchor=H1072317995&source =machineLearning&selectedTitle=2~4&display_rank=1#H1072317995